创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology PDC In Vitro High-Throughput Pharmacodynamic Evaluation Platform

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-09-04 16:26
  • Views:

(Summary description)In the vast field of life sciences and drug discovery, innovation is an important driving force for progress. As a leader in this field, InnoModels Biotechnology (Beijing) Co., Ltd. has provided unprecedented accuracy and reliability for new drug discovery and development with its PDC (Patient-derived tumor cell) in vitro high-throughput drug efficacy evaluation platform. In this paper, we will discuss the technical advantages, application areas and significance of this innovative platform for drug discovery and development

InnoModels Biotechnology PDC In Vitro High-Throughput Pharmacodynamic Evaluation Platform

(Summary description)In the vast field of life sciences and drug discovery, innovation is an important driving force for progress. As a leader in this field, InnoModels Biotechnology (Beijing) Co., Ltd. has provided unprecedented accuracy and reliability for new drug discovery and development with its PDC (Patient-derived tumor cell) in vitro high-throughput drug efficacy evaluation platform. In this paper, we will discuss the technical advantages, application areas and significance of this innovative platform for drug discovery and development

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-09-04 16:26
  • Views:
Information

In the vast field of life sciences and drug discovery, innovation is an important driving force for progress. As a leader in this field, InnoModels Biotechnology (Beijing) Co., Ltd. has provided unprecedented accuracy and reliability for new drug discovery and development with its PDC (Patient-derived tumor cell) in vitro high-throughput drug efficacy evaluation platform. In this paper, we will discuss the technical advantages, application areas and significance of this innovative platform for drug discovery and development.
Technical Background and Advantages
PDC model is a new generation of tumor model established by short-term culture of surgically resected patient's tumor tissue, or tumor cells obtained from PDX (Patient-Derived Xenograft) model or 3D organoid model that has already been modeled, in an in vitro culture system. This model not only retains the genetic characteristics of the primary tumor, but also maintains the heterogeneity of the patient's tumor, making its pharmacodynamic results highly relevant to the clinic. The PDC in vitro high-throughput pharmacodynamic evaluation platform of InnoModels Biotechnology is based on this model, and through cutting-edge technology, it obtains primary cells highly consistent with patients from the digested products of the PDX model, which provides highly accurate pharmacodynamic evaluations for drug discovery and clinical treatment.
The core strength of the platform is its ability for high-throughput, multi-parameter evaluation. Researchers can simultaneously assess multiple cell phenotypic parameters, such as cell proliferation, cell cycle, and apoptosis, to provide a more comprehensive understanding of drug effects. In addition, PDC technology supports the application of multiple cell types, including tumor cells, primary cells, etc., which is suitable for drug research in different disease areas. This comprehensive approach to cell phenotype assessment makes it possible to establish more complex disease models, which helps to study in depth the effects of drugs in complex disease environments.

 


Application Fields and Achievements
InnoModels' PDC in vitro high-throughput drug efficacy evaluation platform has achieved remarkable results in a number of fields. First, in the development and discovery of anti-cancer drugs, the platform accelerates the screening and development process of anti-cancer drugs through the multi-parameter evaluation of tumor cells. Researchers are able to find potential drug candidates more quickly and accurately, bringing hope to tumor patients.
Second, the platform also plays an important role in neurological disease and infectious disease research. By modeling complex neurological diseases, researchers can better understand the effects of drugs in the nervous system and provide new ideas for the treatment of neurodegenerative diseases. Meanwhile, for infectious disease research, the PDC platform provides an efficient and comprehensive in vitro research platform to accelerate the discovery of antiviral drugs.
Clinical value and social significance
In addition to drug screening and R&D, InnoModels' PDC in vitro high-throughput drug efficacy evaluation platform also has important clinical value. By comparing the subject drug with counterpart drugs (e.g., drugs with similar mechanism of action or standardized therapeutic drugs), the platform can predict the clinical efficacy of a drug, providing strong support for the clinical application of the drug. In addition, by comparing the effective rates of different cancer type models, the indications of the drugs can be determined, providing a scientific basis for the clinical use of drugs.
More importantly, the platform is able to search for biomarkers that can predict drug efficacy by analyzing the difference in genetic characteristics between sensitive and resistant models. The discovery of these biomarkers not only helps to optimize drug treatment protocols and improve therapeutic efficacy, but also provides an important reference for individualized medicine and promotes the personalized development of the medical industry.
Conclusion
The emergence of the InnoModels Biotechnology PDC in vitro high-throughput drug efficacy evaluation platform has brought unprecedented accuracy and reliability to drug development and clinical treatment. With its unique technological advantages and wide range of applications, the platform is leading a new era of drug development. We expect that InnoModels Biotechnology will continue to play a leading role in the field of life sciences in the future and make greater contributions to human health.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司